Non-Disclosure Agreement Prospective Licensee Template

Free Word download β€’ Edit online β€’ Save & share with Drive β€’ Export to PDF

3 pagesβ€’25–30 min to fillβ€’Difficulty: Complexβ€’Signature requiredβ€’Legal review recommended
Learn more ↓
FreeNon-Disclosure Agreement Prospective Licensee Template

At a glance

What it is
A Non Disclosure Agreement for a Prospective Licensee is a legally binding contract between an IP owner (licensor) and a party evaluating a potential license (prospective licensee) that restricts how disclosed confidential information β€” trade secrets, proprietary formulas, source code, or product designs β€” may be used or shared. This free Word download lets you customize the scope, permitted purpose, duration, and remedies, then export as PDF for signature before any licensing conversation begins.
When you need it
Use it before sharing proprietary technology, product specifications, financial data, or trade secrets with any party evaluating a license arrangement β€” including distributors, manufacturers, joint-venture partners, or potential sub-licensees. Execute it before any substantive disclosure, not after.
What's inside
Definition of confidential information, permitted-use restriction tied to the licensing evaluation, obligations of the prospective licensee, exclusions from confidentiality, term and survival provisions, return or destruction of materials, IP ownership confirmation, remedies for breach, and governing law.

What is a Non Disclosure Agreement for a Prospective Licensee?

A Non Disclosure Agreement for a Prospective Licensee is a legally binding contract between an IP owner β€” the disclosing party β€” and a third party evaluating a potential license of that IP β€” the receiving party. It restricts the prospective licensee to using any disclosed confidential information solely for the purpose of assessing the licensing opportunity, prohibits further disclosure to outside parties, and expressly confirms that no rights or license in the underlying intellectual property are conveyed by signing. The agreement covers trade secrets, proprietary formulas, source code, technical drawings, financial projections, and any other non-public information exchanged during licensing negotiations, and it typically survives the expiration of the evaluation period for trade-secret obligations indefinitely.

Why You Need This Document

Without a signed NDA in place before licensing discussions begin, every technical presentation, data room disclosure, and product demonstration is an unprotected gift. A prospective licensee who receives detailed IP without a confidentiality obligation faces no legal barrier to using that information to build a competing product, share it with a rival bidder, or simply walk away with your know-how after negotiations collapse. Trade-secret protection requires that you take reasonable steps to maintain secrecy β€” and an executed NDA is the clearest evidence of those steps. Beyond protection, the agreement establishes the legal basis for emergency injunctive relief if a breach occurs, because monetary damages for IP misappropriation are often incalculable once disclosure has happened. This template gives you a jurisdiction-ready, IP-specific NDA β€” including a no-license-grant clause, trade-secret survival provisions, and a compelled-disclosure procedure β€” that you can execute in minutes before any substantive conversation takes place.

Which variant fits your situation?

If your situation is…Use this template
Both parties will share confidential information with each otherMutual Non Disclosure Agreement
One-way disclosure to an employee rather than a licenseeEmployee Non Disclosure Agreement
Disclosing confidential details to a vendor or service providerNon Disclosure Agreement (Unilateral)
Full licensing arrangement is already agreed and ready to executeLicense Agreement
Sharing business information in advance of a potential acquisitionNon Disclosure Agreement for M&A
Protecting confidential information shared with a consultantConsulting Non Disclosure Agreement
Covering trade secrets shared with a joint venture partnerJoint Venture Non Disclosure Agreement

Common mistakes to avoid

❌ Sharing information before the NDA is signed

Why it matters: Once confidential information is disclosed, the NDA cannot retroactively protect it unless a prior written NDA is in place. A prospective licensee who receives data before signing has no binding obligation of confidentiality.

Fix: Establish a firm rule: no data room access, no technical presentation, and no term sheet until both parties have executed the NDA. Use countersignature confirmation as your trigger.

❌ Limiting the confidential information definition to marked written documents

Why it matters: Oral presentations, product demonstrations, and facility tours often reveal the most sensitive IP details β€” excluding them from the definition leaves the most valuable disclosures unprotected.

Fix: Define confidential information to include oral, visual, and electronic disclosures regardless of marking, and require the receiving party to treat all information exchanged in the context of the Purpose as confidential.

❌ Accepting a broad residuals clause

Why it matters: A residuals carve-out allows the receiving party to use anything retained in employees' unaided memories β€” effectively permitting employees who reviewed your formulas or source code to use that knowledge freely after the NDA ends.

Fix: Reject residuals clauses for IP-intensive licensing negotiations. If the counterparty insists, limit residuals to non-technical general business knowledge and expressly exclude trade secrets.

❌ Using a generic two-year survival period for all confidential information including trade secrets

Why it matters: Trade-secret protection under the Defend Trade Secrets Act (US) and equivalent statutes is indefinite as long as secrecy is maintained. A contractual two-year cap gives away decades of legal protection.

Fix: Bifurcate the survival clause: indefinite survival for trade secrets, a defined period (three to five years) for other confidential information. Identify which disclosures constitute trade secrets at the time of disclosure.

❌ Omitting the no-license-grant clause

Why it matters: Without it, a prospective licensee who ultimately decides not to execute a license may argue that access to the IP under the NDA implies a narrow implied license to use what they learned. Courts have occasionally accepted this argument.

Fix: Include an explicit no-license-grant provision in every NDA that involves IP disclosure, and have the receiving party acknowledge it separately in the signature block if the stakes are high.

❌ Choosing a governing law with no connection to the parties or the IP

Why it matters: Courts routinely decline to enforce choice-of-law clauses that have no meaningful relationship to the dispute β€” particularly in California and the EU β€” and apply local law instead, which may offer weaker or different protection.

Fix: Choose the governing law of the jurisdiction where the disclosing party is incorporated or where the IP is registered and primarily exploited. If parties are in different jurisdictions, take legal advice on the most protective and enforceable choice.

The 10 key clauses, explained

Parties and recitals

In plain language: Identifies the disclosing party (licensor or IP owner) and the receiving party (prospective licensee) by full legal name, and states that the purpose of disclosure is to evaluate a potential licensing arrangement.

Sample language
This Non Disclosure Agreement ('Agreement') is entered into as of [DATE] by and between [LICENSOR LEGAL NAME], a [STATE/COUNTRY] [ENTITY TYPE] ('Disclosing Party'), and [PROSPECTIVE LICENSEE LEGAL NAME], a [STATE/COUNTRY] [ENTITY TYPE] ('Receiving Party'), in connection with the Receiving Party's evaluation of a potential license of [DESCRIPTION OF IP] (the 'Purpose').

Common mistake: Using a trade name instead of the registered legal entity name for either party β€” if enforcement becomes necessary, a mismatch between the agreement and corporate registry records can complicate standing to sue.

Definition of confidential information

In plain language: Sets out precisely what information is protected β€” typically all non-public technical, business, and financial information related to the IP, whether disclosed orally, in writing, or by inspection, and how it must be marked or designated.

Sample language
'Confidential Information' means all non-public information disclosed by the Disclosing Party relating to [IP DESCRIPTION], including technical data, trade secrets, formulas, source code, product designs, financial projections, and customer data, whether disclosed orally, in writing, electronically, or by inspection, and whether or not marked 'Confidential.'

Common mistake: Limiting the definition to written, marked materials only. Oral disclosures and demonstrations β€” often the most sensitive exchanges in licensing negotiations β€” are left unprotected unless the definition expressly includes them.

Permitted purpose

In plain language: Restricts the receiving party's use of confidential information strictly to evaluating whether to enter into a licensing agreement with the disclosing party, and prohibits any other use.

Sample language
The Receiving Party shall use the Confidential Information solely for the purpose of evaluating a potential licensing arrangement with the Disclosing Party concerning [IP DESCRIPTION] (the 'Purpose') and for no other purpose whatsoever.

Common mistake: Drafting the permitted purpose too broadly β€” e.g., 'evaluating a business relationship' β€” which allows the receiving party to argue the information was used for a permissible purpose even if no license was ever pursued.

Obligations of the receiving party

In plain language: States the receiving party's duties: maintain the confidentiality of disclosed information using at least the same care as for its own confidential information (and no less than reasonable care), limit access to employees with a need to know, and bind those employees to equivalent obligations.

Sample language
The Receiving Party shall: (a) hold all Confidential Information in strict confidence using no less than reasonable care; (b) not disclose Confidential Information to any third party without prior written consent; and (c) limit access to employees, contractors, and advisors who have a need to know for the Purpose and who are bound by written confidentiality obligations no less restrictive than those in this Agreement.

Common mistake: Omitting the requirement to bind employees and advisors with access to written obligations β€” if a receiving party's employee independently discloses the information, the licensor has no direct recourse against that individual.

Exclusions from confidentiality

In plain language: Lists the standard circumstances under which the receiving party's obligations do not apply β€” information already in the public domain, already known before disclosure, independently developed, or received lawfully from a third party.

Sample language
The obligations of this Agreement do not apply to information that: (a) is or becomes publicly available through no fault of the Receiving Party; (b) was already known to the Receiving Party prior to disclosure, as evidenced by written records; (c) is independently developed by the Receiving Party without use of Confidential Information; or (d) is received from a third party not under a confidentiality obligation to the Disclosing Party.

Common mistake: Agreeing to a broad residuals carve-out that exempts anything retained in employees' unaided memory. This clause can render trade-secret protection meaningless for software, formulas, and technical know-how.

No license grant and IP ownership

In plain language: Expressly states that signing the NDA does not transfer any rights, title, or license in the confidential information or underlying IP to the receiving party β€” the disclosing party retains full ownership.

Sample language
Nothing in this Agreement grants the Receiving Party any rights in or to the Confidential Information or any underlying intellectual property. All Confidential Information remains the exclusive property of the Disclosing Party. No license, express or implied, is granted by this Agreement.

Common mistake: Omitting this clause entirely and relying on the permitted-purpose restriction alone. Without an express no-license statement, a court applying implied-license doctrine could find that access to information implies a narrow right to use it.

Term and survival

In plain language: Sets the duration of the agreement β€” typically one to three years from the date of signing β€” and specifies that obligations relating to trade secrets survive expiration indefinitely, while other confidentiality obligations survive for a defined period.

Sample language
This Agreement shall remain in effect for [X] years from the Effective Date, unless earlier terminated by either party on [30] days' written notice. Notwithstanding any expiration or termination, obligations with respect to information constituting a trade secret shall survive indefinitely; all other confidentiality obligations shall survive for [X] years following expiration.

Common mistake: Setting a uniform two-year survival period for all confidential information, including trade secrets. Statutory trade-secret protection can last decades β€” capping it contractually gives away protection the law would otherwise provide.

Return and destruction of materials

In plain language: Requires the receiving party to promptly return or certify the destruction of all confidential materials β€” documents, copies, digital files, and derivative works β€” upon request or when the Purpose concludes.

Sample language
Upon request by the Disclosing Party or upon conclusion of the Purpose, the Receiving Party shall promptly: (a) return all Confidential Information in tangible form; or (b) certify in writing the permanent destruction of all such materials and copies, including digital files and notes containing Confidential Information.

Common mistake: Failing to include digital files and derivatives (notes, analyses, and models based on disclosed information) in the return/destruction obligation β€” physical documents are returned but the receiving party retains detailed spreadsheets built on the licensor's proprietary data.

Compelled disclosure

In plain language: Addresses what happens if a court or regulator orders the receiving party to disclose the confidential information β€” requires prompt notice to the disclosing party so it can seek a protective order before disclosure occurs.

Sample language
If the Receiving Party is required by law, regulation, or court order to disclose any Confidential Information, it shall: (a) provide prompt prior written notice to the Disclosing Party to allow it to seek a protective order; (b) cooperate with the Disclosing Party in seeking such protection; and (c) disclose only that portion of the Confidential Information legally required.

Common mistake: No compelled-disclosure clause at all, leaving the receiving party free to comply with a subpoena or regulatory request without warning the disclosing party β€” who loses the opportunity to obtain a protective order.

Remedies and governing law

In plain language: States that breach will cause irreparable harm entitling the disclosing party to seek injunctive relief without proving monetary damages, and specifies the governing law and venue for disputes.

Sample language
The Receiving Party acknowledges that breach of this Agreement would cause irreparable harm for which monetary damages would be an inadequate remedy, and that the Disclosing Party is entitled to seek injunctive or other equitable relief without bond. This Agreement is governed by the laws of [STATE/COUNTRY], and any disputes shall be resolved in the courts of [VENUE].

Common mistake: Choosing a governing law that has no connection to where either party operates. Courts in California, for example, may not enforce a choice-of-law clause that attempts to apply a different state's trade-secret law to avoid California's stricter non-compete and IP protections.

How to fill it out

  1. 1

    Identify both parties by full legal name

    Enter the licensor's registered legal entity name and the prospective licensee's full legal name. Include entity type (LLC, Inc., Ltd.) and state or country of incorporation for both parties.

    πŸ’‘ Cross-check each party's name against its corporate registry filing β€” a single-word mismatch can complicate enforcement.

  2. 2

    Define the confidential information precisely

    Describe the IP or information being protected with enough specificity that a court could determine whether a given item falls within the definition. Include oral disclosures, demonstrations, and derivative works, not just marked written documents.

    πŸ’‘ If the IP includes both patented and unpatented elements, distinguish them β€” patent applications become public, but surrounding know-how may remain a trade secret.

  3. 3

    State the permitted purpose narrowly

    Limit the permitted purpose to evaluating a specific potential licensing arrangement. Name the IP or technology by type. Avoid generic language like 'business purposes' or 'exploring a relationship.'

    πŸ’‘ The narrower the permitted purpose, the easier it is to prove misuse if the prospective licensee uses your information to build a competing product.

  4. 4

    Set the obligations and need-to-know access controls

    Specify the standard of care (reasonable care or the same care as the receiving party uses for its own confidential information, whichever is higher), identify permitted recipients (employees, contractors, advisors), and require that those recipients be bound by written obligations.

    πŸ’‘ Add a clause requiring the receiving party to maintain a log of individuals given access β€” this is rarely resisted and is invaluable if a leak occurs.

  5. 5

    Confirm the no-license grant and IP ownership

    Ensure the agreement expressly states that no rights, title, or license in the confidential information or underlying IP are transferred to the prospective licensee by virtue of this NDA.

    πŸ’‘ If a subsequent license is executed, the NDA's no-license clause should be superseded by the license agreement β€” include a merger or supersession clause to clarify the relationship between the two documents.

  6. 6

    Set the term and survival provisions

    Enter the agreement duration (typically one to three years for a licensing evaluation) and ensure trade-secret obligations survive indefinitely while other obligations survive for at least two to five years post-expiration.

    πŸ’‘ For pharmaceutical, biotech, or semiconductor IP, consider extending general confidentiality survival to ten years β€” standard two-year survival is inadequate for long product cycles.

  7. 7

    Include return/destruction and compelled-disclosure obligations

    Specify that all materials β€” physical and digital, including derivative analyses β€” must be returned or destroyed on request, and require advance notice to the licensor before any compelled disclosure to regulators or courts.

    πŸ’‘ Request a written certification of destruction rather than relying on verbal confirmation β€” it creates an audit trail if a dispute arises later.

  8. 8

    Choose governing law and sign before disclosure

    Select the governing law of a jurisdiction with robust trade-secret protection relevant to where the disclosing party operates. Both authorized signatories must execute before any confidential information is shared.

    πŸ’‘ Never share a term sheet, technical data room link, or product demo before the signed NDA is in your files β€” the disclosure itself is the irreversible event.

Frequently asked questions

What is a non disclosure agreement for a prospective licensee?

A non disclosure agreement for a prospective licensee is a legally binding contract that protects confidential information β€” trade secrets, proprietary technology, formulas, or product designs β€” shared by an IP owner with a party evaluating a potential license. It restricts the prospective licensee to using the disclosed information only for the purpose of assessing the licensing opportunity, and prohibits further disclosure or independent use. It does not itself grant any license to the underlying IP.

What is the difference between this NDA and a standard mutual NDA?

A standard mutual NDA creates reciprocal confidentiality obligations β€” both parties disclose and both parties protect. A prospective licensee NDA is typically one-directional: the licensor discloses IP and proprietary details; the prospective licensee receives and protects them. Because the information flow is asymmetric, the obligations and remedies are weighted toward the licensor's protection. Use a mutual NDA only if the prospective licensee will also share its own confidential technology or business data during the evaluation.

When should this NDA be signed?

The NDA must be executed before any confidential information is shared β€” before sending a data room link, before a technical demonstration, and before sharing product specifications or financial projections. Retroactive NDAs are difficult to enforce and may leave pre-signature disclosures unprotected. Treat the countersigned NDA as the unlock event for any substantive discussion.

Does this NDA grant the prospective licensee any rights to use the IP?

No. A well-drafted prospective licensee NDA expressly states that no license, express or implied, is granted by the agreement. The receiving party may review the confidential information solely to evaluate whether to enter into a license. Actual rights to use the IP are granted only by a separate, fully negotiated license agreement executed after the evaluation concludes.

How long should the NDA last?

Most prospective licensee NDAs run one to three years β€” long enough to cover the evaluation and negotiation period. However, obligations relating to trade secrets should survive the agreement's expiration indefinitely, because trade- secret protection under statutes like the US Defend Trade Secrets Act does not expire as long as secrecy is maintained. Cap general confidentiality at three to five years post-expiration; leave trade-secret obligations open-ended.

Can a prospective licensee be required to destroy confidential materials after deciding not to proceed?

Yes, and the NDA should specifically require it. The return-or-destruction clause should cover all tangible and digital materials, including copies, notes, analyses, and models derived from the disclosed information. Request a written certification of destruction rather than relying on verbal confirmation. Retaining the certification creates an enforceable record if the prospective licensee later uses the information.

What remedies are available if the prospective licensee breaches the NDA?

The primary remedy for NDA breach involving IP disclosure is injunctive relief β€” a court order preventing further use or disclosure β€” because monetary damages are often impossible to quantify once confidential information is out. The NDA should include a clause acknowledging that breach causes irreparable harm and that the disclosing party is entitled to seek emergency injunctive relief without posting bond. Monetary damages, attorney's fees, and disgorgement of profits may also be available depending on jurisdiction and the specific breach.

Is this NDA enforceable if the prospective licensee is in a different country?

Cross-border NDA enforcement is possible but jurisdiction-dependent. Courts in most common-law countries (US, UK, Canada, Australia) will enforce foreign NDAs if the governing-law clause has a reasonable connection to the parties and the dispute. EU courts apply local data-protection and trade-secret laws regardless of contractual choice of law in some cases. For high-value cross-border licensing negotiations, include an international arbitration clause (ICC or WIPO) rather than relying solely on domestic courts.

Does this NDA need to be notarized?

Notarization is not required for a prospective licensee NDA to be legally binding in the US, Canada, the UK, or the EU. Signature by an authorized representative of each entity is sufficient. Electronic signatures are enforceable under the ESIGN Act (US), PIPEDA (Canada), eIDAS (EU), and the Electronic Communications Act (UK) for NDAs of this type.

How this compares to alternatives

vs Mutual Non Disclosure Agreement

A mutual NDA imposes reciprocal confidentiality obligations on both parties, used when both sides share sensitive information. A prospective licensee NDA is primarily one-directional β€” the licensor discloses IP and the prospective licensee protects it. Use a mutual NDA only if the prospective licensee will also be sharing its own confidential technology or business data during the evaluation period.

vs License Agreement

A license agreement grants the licensee actual rights to use, commercialize, or sublicense the IP under defined terms and royalty structures. A prospective licensee NDA precedes the license and grants no rights β€” it only permits the receiving party to evaluate the IP under confidentiality. Execute the NDA first; if negotiations succeed, supersede it with a fully negotiated license agreement.

vs Non Disclosure Agreement (Unilateral)

A standard unilateral NDA covers one-way disclosure in general business contexts β€” vendors, consultants, or service providers. A prospective licensee NDA adds IP-specific provisions: a no-license-grant clause, IP ownership confirmation, permitted-purpose tied specifically to licensing evaluation, and typically stronger return-and-destruction obligations. For licensing contexts, the IP-specific version offers materially better protection.

vs Non Disclosure Agreement for Employees

An employee NDA is embedded in an employment relationship and covers confidentiality of all business information encountered during employment. A prospective licensee NDA is a standalone commercial agreement between separate legal entities with a narrow, defined purpose and a finite term. Using an employee NDA template for a licensing counterparty creates mismatched obligations and missing IP-specific protections.

Industry-specific considerations

Pharmaceuticals and Biotech

Formulations, clinical trial data, and regulatory dossiers are disclosed under strict NDA before any drug or compound licensing negotiation; survival periods often extend to ten or more years given long product development cycles.

Technology and Software

Source code, proprietary algorithms, and API architecture shared with prospective software licensees or OEM partners require a definition of confidential information broad enough to capture oral technical discussions and live demonstrations.

Manufacturing and Industrial

Proprietary production processes, technical drawings, and equipment specifications shared with contract manufacturers or component licensees are covered; the NDA typically restricts reverse engineering and competitive use explicitly.

Entertainment and Media

Scripts, character IP, format bibles, and unreleased creative works disclosed to prospective content licensees or distribution partners require clear permitted-purpose restrictions to prevent independent development of similar properties.

Jurisdictional notes

United States

Trade secrets are protected federally under the Defend Trade Secrets Act (DTSA, 2016) and by state law under Uniform Trade Secrets Act statutes adopted in most states. The DTSA allows federal civil claims and emergency ex parte seizure orders. California courts scrutinize NDA scope and may reject overbroad definitions or residuals exclusions. Choose the governing-law state carefully β€” Delaware and New York are common choices for cross-state licensing transactions.

Canada

Canada has no federal trade-secrets statute equivalent to the DTSA; protection flows from common-law breach-of-confidence claims and provincial trade-secrets legislation in some provinces. NDA obligations are enforceable but courts apply a reasonableness standard to duration and scope. Quebec contracts should be drafted in French or bilingual form for provincially regulated entities. Electronic signatures are valid under PIPEDA and provincial equivalents.

United Kingdom

The UK Trade Secrets (Enforcement, etc.) Regulations 2018 (implementing the EU Trade Secrets Directive pre-Brexit) provide a statutory framework for trade-secret misappropriation claims. Courts actively enforce prospective licensee NDAs and will grant interim injunctions to prevent disclosure. Post-Brexit, UK courts are no longer bound by CJEU interpretations but the substantive law remains closely aligned. English law is a common and well-regarded governing-law choice for international licensing NDAs.

European Union

The EU Trade Secrets Directive (2016/943) harmonized trade-secret protection across member states, requiring parties to take reasonable steps to maintain secrecy. The NDA itself is evidence of those reasonable steps. GDPR applies if confidential information includes personal data β€” add a data-processing clause or separate DPA if relevant. Post-termination obligations must comply with local employment and competition laws if any employees are involved in the evaluation. WIPO arbitration is a recommended dispute-resolution mechanism for EU cross-border licensing NDAs.

Template vs lawyer β€” what fits your deal?

PathBest forCostTime
Use the templateStandard one-way IP disclosures in early-stage licensing conversations with domestic counterpartiesFree15–30 minutes
Template + legal reviewLicensing discussions involving patented technology, pharmaceutical data, or cross-border counterparties$300–$800 for a one-hour IP attorney review1–3 days
Custom draftedHigh-value technology transfers, pharmaceutical out-licensing to multinational companies, or disclosures requiring multi-jurisdiction enforcement$1,500–$5,000+1–2 weeks

Glossary

Confidential Information
Specifically defined information β€” trade secrets, designs, formulas, financial data, or technical know-how β€” that the disclosing party designates as protected under the agreement.
Disclosing Party
The IP owner or licensor who shares confidential information with the prospective licensee for evaluation purposes.
Receiving Party
The prospective licensee who receives confidential information and assumes obligations to protect and limit its use.
Permitted Purpose
The narrow, defined reason for which the receiving party may use confidential information β€” typically limited to evaluating a potential licensing arrangement.
Trade Secret
Non-public information that derives economic value from its secrecy and is subject to reasonable efforts by its owner to maintain that secrecy.
Survival Clause
A provision specifying that certain obligations β€” especially confidentiality β€” remain enforceable after the agreement's expiration or termination.
Residuals
General knowledge retained in the unaided memory of employees who reviewed confidential information; some NDAs expressly permit use of residuals, which can significantly weaken protection.
Return or Destruction Obligation
A clause requiring the receiving party to return all confidential materials or certify their destruction upon request or at the agreement's end.
Injunctive Relief
A court order compelling or prohibiting specific conduct β€” typically the primary remedy sought for NDA breach because monetary damages for IP disclosure are often impossible to calculate.
No License Grant
An express statement that the NDA does not itself convey any rights to the confidential information or underlying IP β€” the receiving party gets no license merely by signing.
Exclusions from Confidentiality
Standard carve-outs covering information already public, independently developed by the receiving party, received lawfully from a third party, or required to be disclosed by law or court order.

Part of your Business Operating System

This document is one of 3,000+ business & legal templates included in Business in a Box.

  • Fill-in-the-blanks β€” ready in minutes
  • 100% customizable Word document
  • Compatible with all office suites
  • Export to PDF and share electronically

Create your document in 3 simple steps.

From template to signed document β€” all inside one Business Operating System.
1
Download or open template

Access over 3,000+ business and legal templates for any business task, project or initiative.

2
Edit and fill in the blanks with AI

Customize your ready-made business document template and save it in the cloud.

3
Save, Share, Send, Sign

Share your files and folders with your team. Create a space of seamless collaboration.

Save time, save money, and create top-quality documents.

β˜…β˜…β˜…β˜…β˜…

"Fantastic value! I'm not sure how I'd do without it. It's worth its weight in gold and paid back for itself many times."

Managing Director Β· Mall Farm
Robert Whalley
Managing Director, Mall Farm Proprietary Limited
β˜…β˜…β˜…β˜…β˜…

"I have been using Business in a Box for years. It has been the most useful source of templates I have encountered. I recommend it to anyone."

Business Owner Β· 4+ years
Dr Michael John Freestone
Business Owner
β˜…β˜…β˜…β˜…β˜…

"It has been a life saver so many times I have lost count. Business in a Box has saved me so much time and as you know, time is money."

Owner Β· Upstate Web
David G. Moore Jr.
Owner, Upstate Web

Run your business with a system β€” not scattered tools

Stop downloading documents. Start operating with clarity. Business in a Box gives you the Business Operating System used by over 250,000 companies worldwide to structure, run, and grow their business.

Start freeΒ Β·Β No credit card required